PM
Paul Maciocia
Research areas: Medicine · Oncology · CAR-T cell therapy research · T-cell and B-cell Immunology · Immunotherapy and Immune Responses
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (15)
- CD19 chimeric antigen receptor T‐cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy Save
- Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia Save
- CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? Save
- Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies Save
- Single‐centre experience of implementing physiotherapist‐led prehabilitation for chimeric antigen receptor T cell therapy Save
- Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia Save
- Chimeric antigen receptor T cells for gamma–delta T cell malignancies Save
- Anti-CD1a CAR T cells to selectively target T-ALL Save
- Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Save
- TARGETING THE T-CELL RECEPTOR Β-CONSTANT DOMAIN FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES Save
- Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. Save
- Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy. Save
- Inflammatory signaling in pulmonary arterial hypertension: the controversial role of CRP, and the search for new therapies. Save
- Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Save
- Pain assessment in the paediatric Emergency Department: whose view counts? Save